Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Relatório |
Idioma: | eng |
Título da fonte: | São Paulo medical journal (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657 |
Resumo: | ABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825. |
id |
APM-1_3282d7cc776357e2e1db04b89afce032 |
---|---|
oai_identifier_str |
oai:scielo:S1516-31802021000600657 |
network_acronym_str |
APM-1 |
network_name_str |
São Paulo medical journal (Online) |
repository_id_str |
|
spelling |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysisDexamethasoneCOVID-19SARS-CoV-2Meta-analysis [publication type]Pulmonary medicineCoronavirus pandemicDrug repurposingRespiratory medicineClinical trialsABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825.Associação Paulista de Medicina - APM2021-12-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657Sao Paulo Medical Journal v.139 n.6 2021reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2021.0120.r1.30062021info:eu-repo/semantics/openAccessFerreto,Lirane Elize DefanteBortoloti,Durcelina SchiavoniFortes,Paulo Cezar NunesFollador,FrancieleArruda,GiseleXimenez,João PauloWendt,Guilherme Weltereng2021-11-10T00:00:00Zoai:scielo:S1516-31802021000600657Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2021-11-10T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse |
dc.title.none.fl_str_mv |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
title |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
spellingShingle |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis Ferreto,Lirane Elize Defante Dexamethasone COVID-19 SARS-CoV-2 Meta-analysis [publication type] Pulmonary medicine Coronavirus pandemic Drug repurposing Respiratory medicine Clinical trials |
title_short |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
title_full |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
title_fullStr |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
title_full_unstemmed |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
title_sort |
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis |
author |
Ferreto,Lirane Elize Defante |
author_facet |
Ferreto,Lirane Elize Defante Bortoloti,Durcelina Schiavoni Fortes,Paulo Cezar Nunes Follador,Franciele Arruda,Gisele Ximenez,João Paulo Wendt,Guilherme Welter |
author_role |
author |
author2 |
Bortoloti,Durcelina Schiavoni Fortes,Paulo Cezar Nunes Follador,Franciele Arruda,Gisele Ximenez,João Paulo Wendt,Guilherme Welter |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Ferreto,Lirane Elize Defante Bortoloti,Durcelina Schiavoni Fortes,Paulo Cezar Nunes Follador,Franciele Arruda,Gisele Ximenez,João Paulo Wendt,Guilherme Welter |
dc.subject.por.fl_str_mv |
Dexamethasone COVID-19 SARS-CoV-2 Meta-analysis [publication type] Pulmonary medicine Coronavirus pandemic Drug repurposing Respiratory medicine Clinical trials |
topic |
Dexamethasone COVID-19 SARS-CoV-2 Meta-analysis [publication type] Pulmonary medicine Coronavirus pandemic Drug repurposing Respiratory medicine Clinical trials |
description |
ABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/report |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
report |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1516-3180.2021.0120.r1.30062021 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
dc.source.none.fl_str_mv |
Sao Paulo Medical Journal v.139 n.6 2021 reponame:São Paulo medical journal (Online) instname:Associação Paulista de Medicina instacron:APM |
instname_str |
Associação Paulista de Medicina |
instacron_str |
APM |
institution |
APM |
reponame_str |
São Paulo medical journal (Online) |
collection |
São Paulo medical journal (Online) |
repository.name.fl_str_mv |
São Paulo medical journal (Online) - Associação Paulista de Medicina |
repository.mail.fl_str_mv |
revistas@apm.org.br |
_version_ |
1754209268085555200 |